Evidence map›Paper›PMID 31110724›Full record

ArticleClinical case reports2019

Dose-dependent elevation in amylase and lipase in response to teduglutide administration.

Joshua Lee, Myoung Kim, Dong Wook Kim

Abstract readCase Reports
In one paragraph

Article in Clinical case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joshua LeeBoston University School of Medicine Boston Massachusetts.
Myoung KimBoston University School of Medicine Boston Massachusetts.
Dong Wook KimDepartment of Medicine, Section of Endocrinology, Diabetes, Nutrition and Weight Management Boston University School of Medicine Boston Massachusetts.ORCID https://orcid.org/0000-0001-6106-9894

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Teduglutide has been used for patients with short bowel syndrome. Teduglutide can be a dose-dependent triggering factor to increased amylase and lipase. Serum amylase and lipase levels should be monitored routinely for patients on teduglutide, and they should be screened before the initiation of treatment.

Indexed as

amylaseGLP2lipaseshort bowel syndrometeduglutide

Identifiers

PMID31110724
PMCPMC6509918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.